Clinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell Lymphoma

NCT02340936 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

53

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large B-cell Lymphoma

Interventions

DRUG: LR-ESHAP (lenalidomide 5 mg)
DRUG: LR-ESHAP (lenalidomide 10 mg)
DRUG: LR-ESHAP (lenalidomide 15 mg)
DRUG: LR-ESHAP (lenalidomide 20 mg)

Sponsor

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Collaborators

[object Object]
[object Object]
[object Object]